Cannibalistic cancer eats itself to survive treatment

Stubborn cancer cells play a cunning trick when faced with treatments designed to kill them—they eat themselves to survive. But SAHMRI researchers have found a way to starve the cancer cells, making them more susceptible to cancer therapy.

As researchers develop more personalised cancer therapies that target cancer cells, they are also seeing an increase in resistance to treatment, where patients relapse or no longer respond to treatment.

One way that cancer resists treatment is by undergoing a process where the cancer cells eat themselves to maintain energy levels during times of stress—a process that helps them survive cancer treatments that would otherwise starve them.

Lisa Schafranek, a University of Adelaide PhD student working a SAHMRI, and her colleagues have used a clinically available drug to stop leukaemia cells from eating themselves to survive .

"We've managed to block the self-eating process at a stage where the cell would normally break down its food into energy," says Lisa. "The cell still eats itself, but it can't transform that food into anything useful. So in the end, the cell essentially starves by eating itself to death.

"By preventing the cancer cells from self-eating, we're cutting off their escape route and forcing them to face the cancer therapy."

Their treatment uses a clinically available drug, which was originally developed as an antibiotic to treat lung infections.

"Italian researchers first noticed in 2012 that leukaemia patients being treated with the antibiotic responded much better to the cancer therapy than they had before," explains Lisa. "So we've taken that observation and gone further to understand more about how it actually works on a cellular level."

As a result of these findings, a small-scale human trial of combined antibiotic–cancer therapy has recently begun in Italy.

"Right now, we're focussing on finding effective treatment options for people suffering from leukaemia, but this research is also likely to have applications for other types of cancers such as breast or colon cancer," says Professor Timothy Hughes, Head of Translational Leukaemia Research at SAHMRI.

This work provides a way of making current cancer treatments more effective and less likely to leave behind surviving that might re-grow and cause a patient to relapse, or force the patient to stay on cancer treatments for the rest of their life.

Lisa Schafranek was an Australian national finalist of FameLab—a global science communication competition for early-career scientists.

More information: Schafranek L, Leclercq TM, White DL and Hughes TP. "Overcoming resistance to tyrosine kinase inhibitors in chronic myeloid leukaemia by blocking autophagy with clarithromycin." Medical Staff Society Research Prize, May, 2013

Schafranek L, Leclercq TM, White DL, Hughes TP. "Macrolide Antibiotic Clarythromycin targets TKI-induced autophagy in CML cells." HAA Annual Scientific Meeting Oct, 2012

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Bone loss drugs may help prevent endometrial cancer

3 hours ago

A new analysis suggests that women who use bisphosphonates—medications commonly used to treat osteoporosis and other bone conditions—have about half the risk of developing endometrial cancer as women who do not use the ...

Putting the brakes on cancer

Dec 19, 2014

A study led by the University of Dundee, in collaboration with researchers at our University, has uncovered an important role played by a tumour suppressor gene, helping scientists to better understand how ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.